Indaptus Therapeutics, Inc. - Amendment to Schedule 13D

David E. Lazar has filed an amendment to the Schedule 13D for Indaptus Therapeutics, Inc. The filing details a transaction where Lazar sold a significant portion of his holdings, including Series AAA and Series AA Preferred Stock, for $11.2 million. Following this transaction, Lazar resigned as co-CEO but remains on the Board of Directors. His ownership percentage has decreased significantly, and the filing provides details on the terms of the sale, escrow arrangements, and representations made by both seller and purchasers. The transaction involved the sale of preferred stock convertible into common stock, and the filing outlines the potential future ownership percentages post-conversion.